medigraphic.com
Colegio de Medicina Interna de México.

2013, Number 4

<< Back Next >>

Med Int Mex 2013; 29 (4)

Relationship of Intravascular Microangiopathic Hemolysis and Renal Dysfunction in Patients with Preeclampsia

Duarte-Mote J, Jiménez AJM, Lee-Eng CV, Romero FS, Espinosa LRF, Jiménez AMC, Sánchez RG, Verduzco PJ, Calvo CJ

Language: Spanish
References: 27
Page: 351-355
PDF size: 177.20 Kb.


ABSTRACT

Background: Preeclampsia is today one of the most important causes of maternal morbidity and mortality. Renal dysfunction is one of the main complications in such patients and is a marker of severity of the process. The microangiopathic intravascular hemolysis is a manifestation of severe endothelial dysfunction and is related to perfusorious systemic problems in patients with preeclampsia. Microangiopathic intravascular hemolysis may be a marker associated with renal dysfunction.
Objective: To determine if thrombotic intravascular hemolysis is a marker of bad evolution in patients with preeclampsia in the immediate postpartum.
Material and method: An observational study included patients with preeclampsia admitted to the Obstetric Unit. Patients were classified into two groups: with renal dysfunction (serum creatinine levels ≥ 0.9 mg/dL) or normal renal function. Microangiopathic intravascular hemolysis was analyzed if patients presented positive peripheral blood smear, hemoglobinuria, elevated levels of lactic acid dehydrogenase and thrombocytopenia.
Results: 81 patients with preeclampsia were included, at entering to Obstetric Unit 23 (28.3%) had renal dysfunction and 58 (71.7%) had normal renal function. At the 24 hours after partum 35 patients (43.2%) had renal dysfunction and 46 (56.8%) had normal renal function. Microangiopathic intravascular hemolysis was presented in six patients at entering and after 24 hours (7.4%). Al entering 17.3% and 3.4% of patients with renal dysfunction and normal renal function, respectively, presented microangiopathic intravascular hemolysis, OR 5.89 (95 CI 0.9-34.7) p = 0.031. At the 24 hours after partum 11.4% had renal dysfunction and 4.3% had normal renal function, OR 2.83 (95 CI 0.4-16.4) p = 0.2. In regard to peripheral blood smear, to the admission of the patients, 60.8% had renal dysfunction and 36.2% had normal renal function, OR 2.74 (CI 1.01-7.40) p = 0.0043. To 24 hours, 60% had renal dysfunction and 30.4% had normal renal function, OR 3.42 (95 CI 1.36-8.62) p = 0.008.
Conclusion: Microangiopathic intravascular hemolysis has an inconsistent behavior in relation to renal dysfunction, in contrast to the presence of blurred cells on the peripheral blood smear.


REFERENCES

  1. Barton JR. Hypertension in pregnancy. Ann Emerg Med 2008;51:S16-S17.

  2. Pridjian G, Puschett JB. Preeclampsia. Part 1: clinical and pathophysiologic considerations. Obstet Gynecol Surv 2002;57:598-618.

  3. Gómez Bravo Topete E, Briones-Garduño JC, Morales- Esquivel JG, Rodríguez-Roldán M. Mortalidad materna en el Estado de México. Rev Asoc Mex Med Crit y Ter Int 2003;17:199-203.

  4. Solomon C. Preeclampsia-searching for the cause. N Engl J Med 2004;350:641-642.

  5. Joey P, Alexander BT, Llimas MT, Bennet WA, Khalil RA. Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction. Hypertension 2001;38:718-722.

  6. McKeeman GC. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obst Gynecol 2004;191:1240-1246.

  7. Chesley LC. History and epidemiology of preeclampsiaeclampsia. Clin Obstet Gynecol 1984; 27:801-820.

  8. Paul DS. Elevated asymmetric dimethylarginine concentrations precede clinical preeclampsia, but not pregnancies with small-for-gestational-age infants Am J Obstet Gynecol 2008;198:112.e1-112.e7

  9. Acosta AH. Complicaciones, evolución y manejo postparto de la hipertensión arterial en un grupo de pacientes eclámpticas. Universidad Nacional del Nordeste. Comunicaciones Científicas y Tecnológicas, Cuba, 2006.

  10. Luttun A, Carmeliet P. Soluble EGF receptor Flt1: the elusive preeclampsia factor discovered? J Clin Invest 2003;111:600-602.

  11. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 2003;102:181-192.

  12. Maynard SE, Min JY, Merchan J, Lin KH, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-658.

  13. Buhimschi CS. Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am J Obstet Gynecol 2005;192:734-741.

  14. Fisher SJ, Roberts JM. Defects in placentation and placental perfusion. In: Linhheimer MD, Roberts JM, Cunningham FG, editors. Chesley’s Hypertensive Disorders in Pregnancy. 2nd ed. Stanford: Appleton & Lange, 1999;377-394.

  15. Chambers JC, Fusi L, Malik IS, Haskard DO, et al. Association of maternal endothelial dysfunction with preeclampsia. JAMA 2001;285:1607-1612.

  16. Moore LE. Recurrent risk of adverse pregnancy outcome. Obstet Gynecol Clin North Am 2008;35:459-471.

  17. Zhou Y, McMaster M, Woo K, Janatpour M, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002;160:1405-1423.

  18. Koga K, Osuga Y, Yoshino O, Hirota Y, et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003;88:2348-2351.

  19. Sibai BM. Diagnosis, controversies and management of the HELLP syndrome. Obstet Gynecol 2004;103:981-991

  20. Sibai BM, Stella CL. Diagnosis and management of atypical preeclampsia-eclampsia. Am J Obstet Gynecol 2009;200:481.e1-481.e7.

  21. Gómez Bravo-Topete E, Morales-Esquivel JG, Briones- Vega CG, Díaz-de León-Ponce M, Briones-Garduño JC. Dímero D en preeclampsia-eclampsia. Cir Ciruj 2002;70:98-101.

  22. Meher S, Duley L. Óxido nítrico para la prevención de la preeclampsia y sus complicaciones (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008 Número 2. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2008 Issue 2. Chichester, UK: John Wiley & Sons, Ltd.).

  23. Wilson ML, Goodwin TM, Pan VL, Ingles SA. Molecular epidemiology of preeclampsia. Obstet Gynecol Surv 2003;58:39-66.

  24. O’Brien TE. Maternal body mass index and the risk of preeclampsia: a systematic overview. Epidemiology 2003;14:368-374.

  25. Grundmann M, Woywodt A, Kirsch T, Hollwitz B, et al. Circulating endothelial cells: a marker of vascular damage in patients with preeclampsia. Am J Obstet Gynecol 2008;198:317.e1-317.e5.

  26. Ramsay JE, Stewart F, Greer IA, Sattar N. Microvascular dysfunction: a link between pre-eclampsia and maternal coronary heart disease. BJOG 2003;110:1029-1031.

  27. Peterson E. Risk factors for postpartum antihypertensive medication requirement in severe preeclampsia. Hypertens Pregnancy 2010;29:350-356.




2020     |     www.medigraphic.com